NCT01308840 - Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions

Biliary Tract CancerGallbladder Cancer

Interventions

DRUG

Panitumumab

Day 1 and 15 = 6 mg/kg IV

DRUG

oxaliplatin

Days 1 and 15 = 85mg/m2 IV

DRUG

gemcitabine

Days 1 and 15 = 1000 mg/m2 IV

Trial Locations (2)

University of Rochester Medical Center, Rochester

Dana-Farber / Harvard Cancer Center, Boston